Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $33.1 million.

  • Ocular Therapeutix's Share-based Compensation rose 76.04% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 29.04%. This contributed to the annual value of $33.1 million for FY2024, which is 85.74% up from last year.
  • Per Ocular Therapeutix's latest filing, its Share-based Compensation stood at $33.1 million for FY2024, which was up 85.74% from $17.8 million recorded in FY2023.
  • Ocular Therapeutix's Share-based Compensation's 5-year high stood at $33.1 million during FY2024, with a 5-year trough of $7.5 million in FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $17.8 million (2023), whereas its average is $22.6 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Share-based Compensation declined by 14.02% in 2020, and later skyrocketed by 98.88% in 2021.
  • Over the past 5 years, Ocular Therapeutix's Share-based Compensation (Yearly) stood at $7.5 million in 2020, then surged by 98.88% to $15.0 million in 2021, then increased by 13.26% to $17.0 million in 2022, then rose by 5.08% to $17.8 million in 2023, then skyrocketed by 85.74% to $33.1 million in 2024.